A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Sponsor
Peking University Third Hospital
Study ID
NCT05600998
Status
Unknown

Conditions

  • Ovarian Clear Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks

Study Details

This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma. Study objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with advanced ovarian clear cell carcinoma Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Key Dates

Start date
Oct 30, 2022
Status verified
Oct 2022
Primary completion
Sep 30, 2023
Completion
Feb 28, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Anlotinib
    Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks

Primary Outcome Measure

Objective Response Rate [ Time Frame: 12 weeks ]

Central Contacts

Related Studies